文献速递消化系统肿瘤

CALGB 89803(Alliance)研究中预测的维生素D状态与结肠癌复发和死亡的关系

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
PubMed 文献 · Ann Oncol · 2017-01-01

在CALGB 89803辅助治疗试验的1016例III期结肠癌患者中,前瞻性分析诊断后预测血浆25(OH)D水平对结局的影响。预测25(OH)D最高五分位组较低五分位组的无病生存调整HR为0.62(95%CI 0.44-0.86,Ptrend=0.005),复发无生存和总生存也显著改善。结论认为诊断后较高预测25(OH)D水平可能与复发减少和生存改善相关,需开展辅助维生素D补充的临床试验。

要点

  • 1016例III期结肠癌患者中,预测25(OH)D最高五分位组无病生存HR为0.62(95%CI 0.44-0.86),Ptrend=0.005。
  • 预测25(OH)D较高与复发无生存和总生存显著改善相关(Ptrend分别为0.01和0.0004)。
  • 获益在不同预后因素和分子特征(包括微卫星不稳定及KRAS、BRAF、PIK3CA、TP53突变状态)各分层中似乎一致。

核心结论

  • III期结肠癌诊断后较高的预测25(OH)D水平可能与复发减少和生存改善相关。
  • 作者认为需要在辅助治疗背景下开展评估维生素D补充获益的临床试验。

研究设计与样本

  • 前瞻性分析CALGB 89803(Alliance)辅助治疗试验中1016例III期结肠癌患者。
  • 使用经验证的回归模型计算预测血浆25(OH)D评分。
  • 采用Cox比例风险模型分析预测25(OH)D评分对癌症复发和死亡(无病生存)的影响。

主要发现

  • 预测25(OH)D评分最高五分位组较低五分位组的结肠癌复发或死亡(无病生存)调整HR为0.62(95%CI 0.44-0.86),Ptrend=0.005。
  • 较高的预测25(OH)D评分也与复发无生存和总生存的显著改善相关(Ptrend分别为0.01和0.0004)。
  • 较高预测25(OH)D评分的获益在癌症预后因素和分子肿瘤特征各分层中似乎一致,包括微卫星不稳定及KRAS、BRAF、PIK3CA和TP53突变状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies suggest that higher levels of 25-hydroxyvitamin D3 (25(OH)D) are associated with a reduced risk of colorectal cancer and improved survival of colorectal cancer patients. However, the influence of vitamin D status on cancer recurrence and survival of patients with stage III colon cancer is unknown. PATIENTS AND METHODS: We prospectively examined the influence of post-diagnosis predicted plasma 25(OH)D on outcome among 1016 patients with stage III colon cancer who were enrolled in a National Cancer Institute-sponsored adjuvant therapy trial (CALGB 89803). Predicted 25(OH)D scores were computed using validated regression models. We examined the influence of predicted 25(OH)D scores on cancer recurrence and mortality (disease-free survival; DFS) using Cox proportional hazards. RESULTS: Patients in the highest quintile of predicted 25(OH)D score had an adjusted hazard ratio (HR) for colon cancer recurrence or mortality (DFS) of 0.62 (95% confidence interval [CI], 0.44-0.86), compared with those in the lowest quintile (Ptrend = 0.005). Higher predicted 25(OH)D score was also associated with a significant improvement in recurrence-free survival and overall survival (Ptrend = 0.01 and 0.0004, respectively). The benefit associated with higher predicted 25(OH)D score appeared consistent across predictors of cancer outcome and strata of molecular tumor characteristics, including microsatellite instability and KRAS, BRAF, PIK3CA, and TP53 mutation status. CONCLUSION: Higher predicted 25(OH)D levels after a diagnosis of stage III colon cancer may be associated with decreased recurrence and improved survival. Clinical trials assessing the benefit of vitamin D supplementation in the adjuvant setting are warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT00003835.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Fuchs MA, Yuan C, Sato K, et al. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017. PMID: 28327908. doi:10.1093/annonc/mdx109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。